NEW YORK (GenomeWeb News) – Definiens and Bioscan have signed an agreement to co-market Bioscan’s instruments for noninvasive in vivo animal imaging with Definiens’ image analysis software, the companies said today.
Bioscan, based in Morristown, NJ, and Definiens, based in Munich, Germany, said they have agreed to “conduct cooperative marketing activities and host joint workshops and events” that will offer customers integrated training and implementation programs.
The firms said they will “continue to explore further opportunities for cooperation,” which could include the co-development of user interfaces to incorporate Definiens’ software into Bioscan’s hardware.
Existing Bioscan customers will also receive “introductory offers” for Definiens applications, the partners said.
Bioscan offers the NanoSPECT/CT and NanoPET/CT in vivo animal imaging systems, which analyze molecular function at the nanoliter scale.
Definiens’ Cognition Network Technology software is used for analyzing image data from a range of platforms, including cell and tissue-based assays and in vivo imaging systems.